This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): formoterol fumarate
Description: Perforomist Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists or LABAs. It is a long-acting bronchodilator that is taken by nebulizer. Perforomist Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Critical Therapeutics and Merck KGaA
In March 2007, Critical Therapeutics and DEY, an affiliate of Merck KGaA, signed a definitive co-promotion agreement for Perforomist for Chronic Obstructive Pulmonary Disease (COPD). CT has granted DEY the exclusive rights to negotiate an agreement for the development and commercialization of additional zileuton products and formulations for a specified period.
In June 2007, Critical Therapeutics signed a definitive co-promotion agreement for Perforomist with DEY. The definitive agreement supersedes the binding letter agreement that the two companies entered into in March 2007. Under the terms of the definitive agreement, finalized in June 2007, Critical Therapeutics and DEY will jointly promote Perforomist in the United States. As part of the agreement, Critical Therapeutics agreed to expand its sales force to 40 representatives. Under the terms of the definitive agreement,...See full deal structure in Biomedtracker
Partners: Chiesi Farmaceutici S.p.A.
Additional information available to subscribers only: